Navigation Links
Watson Confirms JALYN™ Patent Challenge
Date:7/22/2011

PARSIPPANY, N.J., July 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market  dutasteride and tamsulosin hydrochloride capsules. Watson's dutasteride and tamsulosin hydrochloride capsules are a generic version of GlaxoSmithKline's JALYN™. JALYN™ capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

GlaxoSmithKline filed suit against Watson on July 21, 2011 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,565,467. GlaxoSmithKline's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until December 30, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

For the twelve months ending May 31, 2011, JALYN™ capsules had total U.S. sales of over $30 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web s
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
2. Watson Confirms Vyvanse® Patent Challenge
3. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings
4. Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
5. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
6. Watson Confirms AVODART(R) Patent Challenge
7. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
8. Watsons Nabumetone Tablets Receive FDA Approval
9. Watson Confirms Pataday™ Patent Challenge
10. Watson Confirms Viagra® Patent Challenge
11. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... July 29, 2014 According to ... "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ENT Navigation ... Size, Share, Growth, Trends and Forecast, 2014 - 2020", ... USD 218.5 million in 2013 and is expected to ... 2020, to reach an estimated value of USD 295.5 ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... (NASDAQ: THOR), a world leader in device-based mechanical circulatory ... said today it will be participating in the Oppenheimer ... 13. Taylor C. Harris, Senior Director of ... on the company, beginning at 10:15 a.m., Eastern Standard ...
... Dec. 9, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, announced that Care360™, the company,s ... e-Prescribing software system by Black Book Rankings, a leading ... services and software industries. Black Book ...
Cached Medicine Technology:Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 2Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 3
(Date:7/29/2014)... 29, 2014 Winter is here down ... afternoon in Sydney’s central business district. That is, until ... costume transformed the otherwise ordinary day into a celebration—a ... are ardent advocates of The Truth About Drugs, a ... Scientology . They woke up the city with a ...
(Date:7/29/2014)... DailyGossip.org reveals in its latest review that the new method ... patients and what they have to go through when cold ... of the new program. Ellie claims that she suffered from ... her very own research. Four years passed until she reached ... Get Rid of Cold Sores program claims that she was ...
(Date:7/29/2014)... Regardless of the good things that happen ... share those with. Love is about understanding, commitment and ... is also about overcoming all the challenges that a ... relationship, women need to know how to understand guys. ... program, please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Want young children ... them something that,s healthy is good for them. Doing ... good, a new study suggests. "Parents and caregivers ... may be better off simply serving the food without ... yummy the food actually is," said study authors Michal ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2
... ... Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for ... ... 10, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome side effects ...
... TUCSON, Ariz. , March 10 If ... of continuing medical education (CME) used by physicians will be ... dramatic increase over the 9% of CME delivered via the ... the winter, 2010 issue of the Journal of Continuing ...
... ... Registered Dietitian Day on March 10, the team behind Skinny in ... combining the best diet and nutrition information with the latest fashion ... ) online directory. Spearheaded by celebrity dietitian Tanya Zuckerbrot, M.S., ...
... ... ... -- A week from today, the Boston branch of the Harvard Business School Alumni ... co-founder Mike “Zappy” Zapolin will be in attendance to present the new website’s business ...
... ... ... ... ...
... may be able to safely lower the platelet ... patients without risking increased bleeding, according to new ... other medical institutions. Reducing platelet transfusions, and ... could help address frequent shortages in platelet supplies, ...
Cached Medicine News:Health News:Thyroid Hormone Analogue for Treating High Cholesterol 2Health News:Thyroid Hormone Analogue for Treating High Cholesterol 3Health News:Study Predicts Half of Physician Continuing Education Will Be Online by 2016 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 3Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 4Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 2Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 4Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 5Health News:Fewer platelets could be used for some cancer and bone-marrow transplantation patients 2
... With a zoom ratio of ... 0.75X to 11.25X, and the ... intervals from 1X to 11X, ... Magnifications of 3.75X to 540X ...
Inquire...
... apochromatically corrected objectives for ... most exacting demands in ... suitable for visual field ... mm and feature sufficiently ...
... working distances with high Numerical Apertures, these ... optical aberrations throughout the visible spectrum from ... across the entire 25mm field of view. ... colour reproduction, plus resolving power at the ...
Medicine Products: